<?xml version="1.0" encoding="UTF-8"?>
<p>The development of synthetic biology and metabolic engineering provides opportunities for the microbial biosynthesis of monoterpenoids (
 <xref rid="B9" ref-type="bibr">Chandran et al., 2011</xref>). Industrial-scale production of some terpenoids using engineered microorganisms have been realized, such as artemisinin acid and ginsenosides (
 <xref rid="B41" ref-type="bibr">Paddon et al., 2013</xref>; 
 <xref rid="B63" ref-type="bibr">Yan et al., 2014</xref>; 
 <xref rid="B56" ref-type="bibr">Wang P. et al., 2015</xref>; 
 <xref rid="B58" ref-type="bibr">Wei et al., 2015</xref>; 
 <xref rid="B64" ref-type="bibr">Yang et al., 2020</xref>). Recovery of the monoterpenoid biosynthetic pathways and introduction of essential key enzymes into proper microbial host can lead to the production of targeted monoterpenoids (
 <xref rid="B65" ref-type="bibr">Zebec et al., 2016</xref>; 
 <xref rid="B24" ref-type="bibr">Ignea et al., 2019</xref>). These provide an alternative way to sustainably supply of monoterpenoids and other Chinese herb-derived natural product (
 <xref rid="B18" ref-type="bibr">Guan et al., 2020</xref>; 
 <xref rid="B55" ref-type="bibr">Wang et al., 2020</xref>).
</p>
